An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma

What is the purpose of this trial?

This study is designed to investigate PT2977 as a treatment for VHL disease associated RCC

Peloton Therapeutics, Inc.

Start Date: 12/20/2018

End Date: 03/01/2020

Last Updated: 12/21/2018

Study HIC#: 2000022827